You are here > News and publications

News and publications

Promethera Biosciences appoints Dr John Tchelingerian as CEO


Mont-Saint-Guibert, Belgium, 23 September, 2015 – Promethera Biosciences, a Belgian biotechnology company developing HepaStem, a cell-based therapy for the treatment of inborn errors of metabolism and acquired liver diseases, has appointed Dr John Tchelingerian as its new Chief Executive Officer. John Tchelingerian joined the company as Chairman of the Board on 8 December, 2014, and has acted as its interim CEO since 23 January, 2015.


Download this file (FR)

Download this file (NL)

Download this file (EN)


PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01

News and Public release

CEO John Tchelingerian to Discuss Strategic Collobarations and Partnering Strategies in Cell Therapy at ARM’s Advanced Therapies Summit
Collaboration to Drive Development and Commercialization of Promethera’s Cell-based Liver-Focused Therapeutics Portfolio in Korea